Proteomics

Dataset Information

0

A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogeniccell death


ABSTRACT: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) functions as a critical stress sentinel that co- ordinates cell survival, inflammation, and immunogenic cell death (ICD). Although the catalytic function of RIPK1 is required to trigger cell death, its non-catalytic scaffold function mediates strong pro-survival signaling. Accordingly, cancer cells can hijack RIPK1 to block necroptosis and evade immune detection. We generated a small-molecule proteolysis-targeting chimera (PROTAC) that selectively degraded human and murine RIPK1. PROTAC-mediated depletion of RIPK1 deregulated TNFR1 and TLR3/4 signaling hubs, accentuating the output of NF-kB, MAPK, and IFN signaling. Additionally, RIPK1 degradation simultaneously promoted RIPK3 activation and necroptosis induction. We further demonstrated that RIPK1 degradation enhanced the immunostimulatory effects of radio- and immunotherapy by sensitizing cancer cells to treat- ment-induced TNF and interferons. This promoted ICD, antitumor immunity, and durable treatment responses. Consequently, targeting RIPK1 by PROTACs emerges as a promising approach to overcome radio- or immunotherapy resistance and enhance anticancer therapies.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Graeme Benstead-Hume  

LAB HEAD: Jyoti Choudhary

PROVIDER: PXD043560 | Pride | 2024-05-23

REPOSITORIES: Pride

Dataset's files

Source:

Similar Datasets

2016-09-07 | E-GEOD-72797 | biostudies-arrayexpress
2021-04-01 | GSE171214 | GEO
2023-06-06 | PXD042579 | Pride
2020-03-23 | PXD014097 | Pride
2021-10-26 | GSE176422 | GEO
2024-04-01 | GSE254754 | GEO
2021-03-18 | PXD003383 | Pride
2020-03-27 | GSE143955 | GEO
2021-10-11 | PXD021366 | Pride
2025-03-06 | PXD059873 | Pride